Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Aralen)
29,653 results
  • Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi. [Journal Article]
    Malar J. 2023 Jan 27; 22(1):32.Nyangulu W, Mungwira RG, … TSCQ Study Team
  • CONCLUSIONS: Recurrent malaria infections are frequent in this population of PWH on ART. The PCR-adjusted efficacy of AL meets the WHO criteria for acceptable treatment efficacy. Nevertheless, lumefantrine levels tend to be low in this population, particularly in those on efavirenz-based regimens, with lower concentrations associated with more frequent malaria infections following treatment. These results highlight the importance of understanding drug-drug interactions when diseases commonly co-occur.
  • Protein degradation: expanding the toolbox to restrain cancer drug resistance. [Review]
    J Hematol Oncol. 2023 Jan 24; 16(1):6.Ming H, Li B, … Huang C
  • Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several therapeutic strategies such as inhibition of proteasome with bortezomib and proteolysis-targeting chimeric have been developed. Compared with intervention at the transcriptional level, targ…
  • Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome. [Review]
    Int J Mol Sci. 2023 Jan 10; 24(2)Arachchillage DJ, Laffan M, Pericleous C
  • Antiphospholipid syndrome (APS) is an acquired highly prothrombotic disorder in which thrombo-inflammatory antiphospholipid antibodies (aPL) cause thrombosis via multiple mechanisms, including endothelial damage and activation. Obstetric complications in APS are caused by placental thrombosis, inflammation and complement activation. Anticoagulation is poorly effective in some patients especially …
  • New Iron Twist to Chloroquine─Upgrading Antimalarials with Immunomodulatory and Antimicrobial Features. [Journal Article]
    J Med Chem. 2023 Jan 20 [Online ahead of print]Aksić J, Genčić M, … Jovanović L
  • Herein, upgraded chloroquine (CQ) derivatives capable of overcoming Plasmodium resistance and, at the same time, suppressing excessive immune response and risk of concurrent bacteremia were developed. Twelve new ferrocene-CQ hybrids tethered with a small azathia heterocycle (1,3-thiazolidin-4-one, 1,3-thiazinan-4-one, or 5-methyl-1,3-thiazolidin-4-one) were synthesized and fully characterized. Al…
  • The evidence base for emergency use authorizations for COVID-19 treatments: A rapid review. [Journal Article]
    Health Sci Rep. 2023 Jan; 6(1):e1051.Knowlson C, Byrne A, … Torgerson D
  • CONCLUSIONS: The number of trials for treatments with EUAs was limited in all cases before the EUA was issued, and in most cases for those with EUAs ongoing at the end of September 2021. The presence of EUAs may discourage participation in relevant clinical trials, which delays the widespread implementation of evidenced-based therapies. Large, robust RCTs should be completed, such as the RECOVERY trial in the United Kingdom, to quickly find the answers desperately required during a pandemic.
New Search Next